# A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

> **NCT04220632** · PHASE1,PHASE2 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 1 (actual)

## Conditions studied

- GVHD,Acute

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Prednisone
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT04220632
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-18
- **Primary completion:** 2020-10-10
- **Final completion:** 2020-10-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Adverse events of the first patient
- **Last updated:** 2020-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220632, "A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04220632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*